title: Effect of conjugated estrogens with and without medrogestone: a prospective study.
abstract: OBJECTIVE
  To study the possible changes in serum lipids and lipoproteins during hormone replacement therapy with special emphasis on the possible effects brought about by the progestogen.
  
  
  METHODS
  Open-label randomized prospective comparative study.
  
  
  METHODS
  Gynecological outpatient department of an university hospital.
  
  
  METHODS
  Thirty-three healthy hysterectomized postmenopausal women.
  
  
  METHODS
  Continuous oral supplementation with conjugated estrogens, 0.625 mg daily, was administered either alone (group I; N = 18) or in combination with cyclic medrogestone, 5 mg daily during the last 12 days of each 28 days treatment cycle (group II; N = 15).
  
  
  METHODS
  Changes in serum lipids, lipoproteins and apolipoproteins after three, six and 13 treatment cycles.
  
  
  RESULTS
  After 1 year of treatment significant increases were observed in mean high-density lipoprotein (HDL) cholesterol, its subfractions, and apolipoprotein A-I in group I and II: HDL cholesterol: +25.2% and +12.1%, respectively; HDL2 cholesterol: +47.4% and +23.5%, respectively; HDL3 cholesterol: +18.1% and +11.2%, respectively; apolipoprotein A-I: +23.0 and +14.8%, respectively. Comparing the two study groups no significant differences were found in lipid changes during the study period, except for HDL2 cholesterol.
  
  
  CONCLUSIONS
  Supplementation with conjugated estrogens, with and without medrogestone, and given for a longer period, demonstrated a beneficial influence on serum lipoproteins with almost no differences between the two treatment regimens.
authors.affiliation: Department of Obstetrics and Gynecology, University Hospital Nijmegen Sint Radboud, The Netherlands.
authors.forename: M J
authors.initials: MJ
authors.lastname: van der Mooren
authors.forename: J A
authors.initials: JA
authors.lastname: Leuven
authors.forename: R
authors.initials: R
authors.lastname: Rolland
mesh_terms: D000284:Administration, Oral; D001053:Apolipoproteins / Q000097:blood; D002784:Cholesterol / Q000097:blood; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D002979:Climacteric / Q000097:blood / Q000187:drug effects*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D015914:Estrogen Replacement Therapy; D004966:Estrogens, Conjugated (USP) / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D006801:Humans; D007044:Hysterectomy; D008055:Lipids / Q000097:blood*; D008074:Lipoproteins / Q000097:blood*; D008524:Medrogestone / Q000008:administration & dosage* / Q000009:adverse effects; D008875:Middle Aged; D011446:Prospective Studies; D014280:Triglycerides / Q000097:blood
chemical_list: D001053:Apolipoproteins; D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D004966:Estrogens, Conjugated (USP); D008055:Lipids; D008074:Lipoproteins; D014280:Triglycerides; D008524:Medrogestone; D002784:Cholesterol